Today: 21 March 2026
Subscribe
Browse Category

NYSE:KVUE 14 October 2025 - 4 November 2025

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kimberly-Clark agreed to acquire Kenvue for $48.7 billion on Nov. 3, 2025, a 46% premium to its prior close. Kenvue shares surged nearly 20% on the news, while Kimberly-Clark stock dropped 13%. The deal follows a turbulent year for Kenvue, including a CEO ouster, falling sales, and litigation over Tylenol safety claims. Kenvue posted $15 billion in 2025 revenue and maintained gross margins near 59%.
4 November 2025
···
Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark shares plunged 14.6% on Nov. 3 to a 52-week low near $102 after announcing a $40 billion cash-and-stock deal to acquire Kenvue at a 46% premium. The drop erased about 15% of KMB’s market value, with the stock now down 21% year-over-year. Investors cited concerns over Kenvue’s litigation risks and debt load. KMB trades at 17.3× earnings, with a 4.9% dividend yield.
4 November 2025
··
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kimberly-Clark announced a $48.7 billion cash-and-stock deal to acquire Kenvue, sending Kenvue shares up about 20% in pre-market trading to near $17.50. Kenvue shareholders will receive $3.50 in cash and 0.14625 KMB shares per KVUE share. Kenvue reported Q3 net profit of $398 million, beating earnings expectations. Kimberly-Clark shares fell roughly 12.5% on the news.
3 November 2025
····
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue shares plunged 13% Thursday to a record low near $14 after news of U.K. lawsuits over Johnson’s Baby Powder, representing 3,000 claimants and potential £1 billion in damages. The stock is down about 34% year-to-date and nearly 40% below its IPO price. Wall Street cut price targets and Moody’s downgraded its outlook to “negative.” Kenvue’s market cap now stands at roughly $30–31 billion.
17 October 2025
···
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue shares hit a 52-week low of $15.46 on Oct. 16, 2025, down about 5% in one day and over 27% in the past year. The company faces new UK talcum-powder lawsuits and ongoing FDA scrutiny over Tylenol, while Q2 revenue fell 4% to $3.84 billion. Moody’s affirmed its A1 rating but cut the outlook to negative. Kenvue replaced its CEO in July and launched a strategic review, considering asset sales.
16 October 2025
·
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Johnson & Johnson will spin off its $9.2 billion orthopedics business as DePuy Synthes within 18–24 months, its second major split since 2023. J&J beat Q3 2025 earnings estimates, raised its full-year revenue outlook to up to $93.9 billion, and saw shares rise 2% on Oct. 14. The move shifts J&J’s focus to higher-growth drug and device segments. CFO Joe Wolk said orthopedics innovation was “in better hands somewhere else.”
14 October 2025
·
1 2 3

Stock Market Today

  • Is Disney Stock Fairly Valued Amid Recent Price Weakness?
    March 21, 2026, 1:51 AM EDT. Disney (DIS) shares have recently weakened, closing at $99.51 with a 7.1% drop over 30 days and 11% year-to-date decline. Over five years, the stock is down 45.2%. Despite mixed performance, Disney's valuation scores 5 out of 6 on Simply Wall St's metrics. A Discounted Cash Flow (DCF) model estimates Disney's intrinsic value at $99.89, nearly matching its current price, suggesting the stock is fairly valued with a slight 0.4% undervaluation. The DCF uses projected free cash flows rising to $14.10 billion by 2030, emphasizing Disney's long-term cash generation prospects. Investors should monitor Disney's valuation as cash flow estimates and market conditions evolve. The P/E ratio and other traditional metrics also provide context for assessing Disney's price relative to earnings and growth expectations.
Go toTop